ImaginAb, Quibim Collaborate to Revolutionize Immune Status Diagnosis and Immunotherapy Prediction

ImaginAb Inc., a global biotechnology company developing the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT), and Quibim, a global company founded with the goal of turning imaging data into actionable predictions, have announced a new collaboration. By combining ImaginAb's investigational CD8 ImmunoPET technology with Quibim's cutting-edge image processing technology, the two partners hope to revolutionise immunotherapy treatment planning.

Immunotherapy has shown remarkable promise in treating cancer and other diseases, but predicting their efficacy remains difficult. CD8 ImmunoPET is an 89Zr-labeled minibody designed to bind to the CD8 receptor on human T cells for non-invasive quantitative PET imaging. This method is currently being studied to see if it can be used to assess a patient's immune status, measure the efficacy of immunotherapies, and predict patient outcomes.

Quibim will develop an imaging-based algorithm to interpret CD8 ImmunoPET PET/CT exams as part of this collaboration, with the goal of quantitatively assessing the efficacy of the 89Zr-labeled minibody in targeting the CD8 receptor in the tumour microenvironment. The algorithm will extract quantitative measures of tracer uptake in the tumour and surrounding tissues using advanced image processing techniques, allowing accurate assessment of the minibody's binding efficacy to CD8 receptors. The quantitative data generated will provide important insights into the minibody's biodistribution and targeting specificity, informing future clinical development of the imaging agent and its potential therapeutic application. "This partnership presents a unique opportunity to broaden the potential applicability of CD8 ImmunoPET by incorporating advanced image processing techniques into image interpretation," said Ian Wilson, CEO of ImaginAb.

We are excited to collaborate with Quibim to further our understanding of immune imaging, with the ultimate goal of improving patient care." ImaginAb and Quibim are collaborating to make significant contributions to the field of immunotherapy, with the goal of improving the lives of countless patients. Keep an eye out for updates on our progress and breakthroughs. A clinical-stage, revenue-generating global biotechnology company that uses its proprietary minibody and cys-diabody platforms to develop next-generation imaging agents and radiopharmaceutical therapy products. Quibim, which has offices in New York, Cambridge, and Valencia, Madrid, and Barcelona in Spain, was founded with the goal of transforming imaging into a catalyst for precision health.